A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
暂无分享,去创建一个
V. Grünwald | L. Bergmann | J. Bedke | P. Goebell | A. Strauß | T. Hilser | A. Hartmann | P. Ivanyi | J. Meiler